[1]
J. Barreto Ribeiro dos Santos, A. Oliveira Lyrio, F. Ferré, T. Pires Mega, A. C. de Freitas Lopes, e L. Fontes Schluckebier Bonan, “Post incorporation monitoring into the Brazilian Public Health System: an analysis of Infliximab, Vedolizumab and Tofacitinib for the treatment of ulcerative retocolitis”, JAFF, vol. 9, nº 1, nov. 2025.